26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
03 September 2024 - QureTech Bio ABQureTech Bio announces the appointment of Markus Thor as new CEOWe are delighted to welcome Markus as the new CEO of QureTech Bio. He has the vision, expertise, and leadership…read more >>
28 August 2024 - QureTech Bio ABQureTech Bio: Scientific publication highlights the potential of GmPcides for treating S. pyogenes infectionsQureTech Bio is happy to report that the scientific publication titled “Dihydrothiazolo ring-fused 2-pyridone antimicrobial compounds treat Streptococcus pyogenes skin…read more >>
28 August 2024 - Destiny Pharma plcDestiny Pharma: FDA grants XF-73 Dermal QIPD for burn woundXF‐73 Dermal's successful US FDA Qualifying Infectious Disease Product application builds on the previously successful US FDA QIDP grant for…read more >>
27 August 2024 - BasileaEuropean Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to BasileaWe are very pleased to have received the European Commission Decision to approve Cresemba for the use in children who…read more >>
05 August 2024 - Destiny Pharma plcDestiny Pharma: XF-73 prevents bacterial invasion of bloodstreamThese results from an in vivo burn wound infection model provide clear evidence that XF-73 can significantly reduce the risk,…read more >>
22 July 2024 - Destiny Pharma plcDestiny Pharma: Treatment of XF-73 Nasal reduces antibiotic useThe data to be presented at ID Week highlights the ability of XF-73 Nasal gel to significantly reduce the need…read more >>
17 March 2025BIO-Europe Spring® 2025 – 19th Annual International Partnering ConferenceBIO-Europe Spring will bring together over 3,700 leading executives from around the world. Specifically, we will host more than 20,000…read more >>
25 February 20259th AMR ConferenceSave the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…read more >>
03 December 2024REVIVE Webinar: Implementation research for the appropriate use of, and access to, antimicrobialsThis webinar will explore how implementation research has successfully led to the updating of guidelines for other drugs and discuss…read more >>
04 November 2024BIO-Europe ® 2024 – 30th Annual International Partnering ConferenceOver the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…read more >>
19 September 2024REVIVE Webinar: An introduction to antibiotic research and development (R&D)Itroduction to the stages from discovery to the phases of clinical trials and pharmaceutical development - A must-watch for clinicians…read more >>
22 August 2024REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three casesFind out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…read more >>
23 July 2024REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobialsIn this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…read more >>
27 June 2024REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspectiveAlisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…read more >>
23 April 2024REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistanceThe next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…read more >>
